Future Directions for mCRC Management
Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Sequencing Therapy for Relapsed mCRC
Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.
Management of Relapsed mCRC
Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.
Dosing Strategies for Regorafenib for Patients With mCRC
Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.
Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC
Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.
Role of Maintenance Therapy in Advanced CRC
Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.
Using ICI Therapy in MSI-High mCRC
Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.
Selecting Frontline Therapy for Newly Diagnosed mCRC
Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.
Role of Genomic Testing in mCRC
Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.
Overview of Colorectal Cancer
Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512